Search

Displaying results 8381 - 8390 of 10000 in total
  1. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. … Multiple myeloma is a cancer where plasma cells rapidly divide out of control.

    Categories: Receptors, Antigen, T-CellSynonyms: Anti-BCMA CAR T cell
  2. Drug

    Zagotenemab

    go.drugbank.com/drugs/DB16674
    Investigational

    Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).

  3. Drug

    Ravagalimab

    go.drugbank.com/drugs/DB16676
    Investigational

    Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis

  4. Drug

    Cadonilimab

    go.drugbank.com/drugs/DB16680
    Investigational

    Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

    Synonyms: 卡度尼利单抗International brands: 开坦尼
  5. Drug

    Efmitermant alfa

    go.drugbank.com/drugs/DB16686
    Investigational

    Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).

  6. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis … [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990]

    Categories: Heterocyclic Compounds, 2-RingSynonyms: NS-2
  7. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. … [A233265] It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.

  8. Drug

    Glutazumab

    go.drugbank.com/drugs/DB16697
    Experimental

    Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.[A235745]

  9. Drug

    Neihulizumab

    go.drugbank.com/drugs/DB16698
    Investigational

    Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.[L34450]

  10. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

    Synonyms: 1-glutamylplasminogen